[et_pb_section fb_built=”1″ custom_padding_last_edited=”off|desktop” _builder_version=”4.16″ background_color=”#26619A” custom_padding=”0px||0px||false|false” custom_padding_tablet=”24vh||2vh||false|false” background_color_gradient_direction_tablet=”360deg” background_color_gradient_stops_tablet=”#2b87da 49%|#29c4a9 79%” background_color_gradient_start_position_tablet=”49%” background_color_gradient_end_position_tablet=”79%” background_size_tablet=”cover” background_position_tablet=”center_right” background_position_phone=”center_right” locked=”off” global_colors_info=”{}”][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#26619a” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_row column_structure=”2_5,3_5″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” custom_padding_last_edited=”on|tablet” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” max_width=”100%” custom_padding=”0px||0px|4%|false|false” custom_padding_tablet=”0px|||0%|false|false” custom_padding_phone=”” locked=”off” global_colors_info=”{}”][et_pb_column type=”2_5″ _builder_version=”4.16″ custom_padding=”30px||||false|false” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_ds_breadcrumbs module_class=”light” _builder_version=”4.5.1″ _module_preset=”default” locked=”on” global_colors_info=”{}”][\/et_pb_ds_breadcrumbs][et_pb_text _builder_version=”4.16″ header_font=”|700|||||||” header_font_size=”42px” header_line_height=”1.15em” background_layout=”dark” width=”80%” max_width=”520px” module_alignment=”center” custom_margin=”3em||20px||false|false” custom_margin_tablet=”3em||||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|desktop” header_font_size_tablet=”34px” header_font_size_phone=”24px” header_font_size_last_edited=”on|desktop” module_alignment_tablet=”” module_alignment_phone=”” module_alignment_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_font_size=”24px” background_layout=”dark” width=”80%” max_width=”520px” module_alignment=”center” custom_margin=”||40px||false|false” custom_padding=”||||false|false” text_font_size_tablet=”20px” text_font_size_phone=”16px” text_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n
The ASPREE trial of low-dose aspirin showed that 100mg of enteric coated aspirin taken daily did not extend life free of disability in older adults.<\/p>\n
ASPREE XT is the continuing longitudinal follow-up of ASPREE participants\u00a0<\/a>seeking opportunities to prevent illness and disability in this age group.<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”3_5″ _builder_version=”4.16″ background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2020\/09\/asprinedit.jpg” custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_code _builder_version=”4.16″ _module_preset=”default” height=”34em” height_tablet=”250px” height_phone=”250px” height_last_edited=”on|phone” global_colors_info=”{}”][\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” padding_right_2=”0px” padding_left_2=”0px” padding_top_bottom_link_2=”false” padding_left_right_link_2=”true” module_class=”texture-left” _builder_version=”4.16″ _module_preset=”default” inner_max_width=”80%” custom_margin=”||||false|false” custom_padding=”||90px||false|false” border_color_bottom=”#bdbec0″ global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”Anchors ” _builder_version=”4.16″ text_font=”||||||||” text_text_color=”#26619a” header_font=”|||on|||||” header_2_font=”|||on|||||” header_2_font_size=”32px” header_3_line_height=”2em” text_font_size_tablet=”28px” text_font_size_phone=”24px” text_font_size_last_edited=”on|phone” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|phone” locked=”off” global_colors_info=”{}”]<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”2_3″ specialty_columns=”2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner admin_label=”PUT CONTENT BELOW AS A TEXT AND IMAGES” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” custom_padding=”|0px||0px|true|true” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”ASPREE clinical trial & XT study summary” _builder_version=”4.16″ _module_preset=”default” text_font=”||||||||” header_font=”||||||||” global_colors_info=”{}”]<\/p>\n ASPREE (ASPirin in Reducing Events in the Elderly) was a large community-based clinical trial undertaken between 2010 and 2017 in Australia and the USA, involving 19,114 older adults: 16,703 participants from across south-eastern Australia and 2,411 from centres across the USA. While the Australian participants were mainly Caucasians aged 70 and above, approximately half of USA participants were ethnic minorities aged 65 years and older. At recruitment all participants were free of overt cardiovascular disease, dementia and physical disability.<\/p>\n The primary objective of the ASPREE trial was to determine whether low-dose aspirin (100mg) could prolong disability-free survival – i.e. life free of dementia or persistent physical disability. Secondary objectives aimed to determine whether low-dose aspirin reduced the incidence of cardiovascular disease, cognitive decline, depression, cancer, physical disability and major bleeding episodes.\u00a0 The principal results were published in the New England Journal of Medicine<\/a> in September 2018.<\/p>\n <\/p>\n The ASPREE-XT study is continuing to follow-up ASPREE participants following cessation of the randomised\u00a0(aspirin or matched placebo) treatment phase. The large majority of participants are no longer taking aspirin. This observational phase of the study is aiming to determine whether any impacts of a prolonged course of aspirin therapy are delayed, as has been suggested with some cancers. ASPREE-XT, in conjunction with various sub-studies, is also examining whether genetic, lifestyle or environmental factors that may contribute to the maintenance of health and identify other opportunities to prevent illness and disability in this age group.<\/p>\n Monash University<\/a> leads the ASPREE project in Australia and the Berman Center for Outcomes and Clinical Research leads in the USA.<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ background_color=”#26619a” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”At A Glance” _builder_version=”4.16″ _module_preset=”d100a70a-4a1b-4c0a-852d-deb7ebdb8d36″ background_layout=”dark” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” make_equal=”on” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”5fc07e0a-53a2-4b20-aac9-883fa2ab9fbb” background_color=”#ffffff” global_colors_info=”{}”][et_pb_code admin_label=”Image (as background)” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2020\/09\/230_Mobile_Labs_Study_Participants_352288.jpg” width=”100%” height=”220px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Project Features” _builder_version=”4.16″ _module_preset=”default” text_line_height=”1.8em” header_2_font=”|600|||||||” header_4_text_align=”center” background_color=”#ffffff” custom_margin=”0px||0px||true|false” custom_padding=”5%|5%|5%|5%|true|true” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”5fc07e0a-53a2-4b20-aac9-883fa2ab9fbb” background_color=”#ffffff” global_colors_info=”{}”][et_pb_code admin_label=”Image (as background)” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2020\/08\/hal-gatewood-iPl3q-gEGzY-unsplashcrop.jpg” width=”100%” height=”220px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Key Publications” _builder_version=”4.16″ _module_preset=”default” text_line_height=”1.8em” header_2_font=”|600|||||||” header_4_text_align=”center” background_color=”#ffffff” custom_margin=”0px||0px||true|false” custom_padding=”5%|5%|5%|5%|true|true” locked=”off” global_colors_info=”{}”]<\/p>\n <\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”5fc07e0a-53a2-4b20-aac9-883fa2ab9fbb” background_color=”#ffffff” global_colors_info=”{}”][et_pb_code admin_label=”Image (as background)” _builder_version=”4.16″ _module_preset=”default” background_image=”https:\/\/aspree.org\/wp-content\/uploads\/sites\/2\/2020\/09\/39_Aspree-Group-and-staff_371748.jpg” width=”100%” height=”220px” custom_margin=”0px||0px||true|false” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][\/et_pb_code][et_pb_text admin_label=”Substudies” _builder_version=”4.16″ _module_preset=”default” text_line_height=”1.8em” header_2_font=”|600|||||||” header_4_text_align=”center” background_color=”#ffffff” custom_margin=”0px||0px||true|false” custom_padding=”5%|5%|5%|5%|true|true” locked=”off” global_colors_info=”{}”]<\/p>\n ASPREE embedded a series of sub-studies<\/a> into the project. These have explored the impact of low-dose aspirin on other conditions associated with ageing including hearing loss, macular disease, bleeding and anaemia.<\/p>\n Published sub-study papers include:<\/a>\u00a0 genomic studies, depression, epigenetics, falls and fractures, sepsis, and sex hormone studies in older women.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ specialty=”on” admin_label=”TABBED CONTENT (LIGHT)” module_class=”tabs” _builder_version=”4.16″ _module_preset=”default” inner_max_width=”80%” custom_margin=”||||false|false” custom_padding=”||90px||false|false” border_width_bottom=”1px” border_color_bottom=”#bdbec0″ global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”TITLE” _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”ASPREE Clinical Trial Protocol” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||20px||false|false” global_colors_info=”{}”]<\/p>\n The ASPREE Clinical Trial Protocol<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”ASPREE-XT study Protocol” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||20px||false|false” global_colors_info=”{}”]<\/p>\n The ASPREE-XT Study Protocol<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”Data Access & Collaboration” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||20px||false|false” global_colors_info=”{}”]<\/p>\n Data access and collaboration<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=”PI Updates” module_class=”tab-link” _builder_version=”4.16″ _module_preset=”default” link_text_color=”#2F2F2F” custom_margin=”||20px||false|false” global_colors_info=”{}”]<\/a>PI updates for researchers[\/et_pb_text][\/et_pb_column][et_pb_column type=”2_3″ specialty_columns=”2″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner admin_label=”TAB CONTENT” module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Header” _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”ASPREE Protocol summary” _builder_version=”4.16″ _module_preset=”default” text_text_color=”#26619a” link_text_color=”#c9a700″ header_2_text_color=”#26619a” header_3_text_color=”#26619a” global_colors_info=”{}”]<\/p>\n Download the ASPREE Clinical Trial Protocol<\/a><\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”TAB CONTENT” module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Header” _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”ASPREE-XT Protocol Summary” _builder_version=”4.20.4″ _module_preset=”default” text_text_color=”#26619a” link_text_color=”#c9a700″ header_2_text_color=”#26619a” header_3_text_color=”#26619a” global_colors_info=”{}”]<\/p>\n Download the ASPREE-XT Study Protocol<\/a><\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”TAB CONTENT” module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Header” _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Data Access & Collaboration” _builder_version=”4.20.4″ _module_preset=”default” text_text_color=”#26619a” link_text_color=”#c9a700″ header_2_text_color=”#26619a” header_3_text_color=”#26619a” global_colors_info=”{}”]<\/p>\n ASPREE clinical trial data is managed through a partnership of USA and Australian study collaborators. Data is available to partnering and external researchers for projects of appropriate scientific merit. Expressions of interest to analyse data from the ASPREE clinical trial and\/or sub-studies including biospecimens, are co-ordinated through the ASPREE Access Management Site<\/a>\u00a0(AMS).<\/p>\n View a list of approved projects in the AMS here<\/a>.<\/p>\n [\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=”TAB CONTENT” module_class=”tab-content” _builder_version=”4.16″ _module_preset=”default” max_width=”840px” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text admin_label=”Header” _builder_version=”4.16″ header_2_font=”|600|||||||” header_2_font_size=”32px” header_2_font_size_tablet=”28px” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|desktop” locked=”off” global_colors_info=”{}”]<\/p>\n [\/et_pb_text][et_pb_text admin_label=”PI Updates” _builder_version=”4.20.4″ _module_preset=”default” text_text_color=”#26619a” link_text_color=”#c9a700″ header_2_text_color=”#26619a” header_3_text_color=”#26619a” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n This brief update aims to keep researchers informed of developments with the ASPREE project. For further information about matters in this newsletter please feel free to contact a study PI.<\/p>\n We are pleased to share that with new funding from the National Cancer Institute in the U.S, ASPREE is beginning its third phase, called ASPREE-LT (Long-Term). This support allows us to continue phone-call\/medical record-based follow up of participants, with a particular focus on cancer and healthy ageing. We are grateful for the ongoing support from our participants, funders and collaborators, which will enable ASPREE-LT to drive impactful research for ageing health.<\/p>\n The ASPREE website maintains a publications list<\/a> which highlights the breadth of research undertaken using ASPREE data. These include:<\/p>\n <\/p>\n Cancer incidence and mortality with aspirin in older adults: follow-up of the ASPREE trial<\/strong> Frailty trajectories after a cardiovascular event among community-dwelling older people<\/strong> Longitudinal changes in heart stress and the risk for cardiovascular disease and mortality in older adults: An observational study<\/strong> <\/p>\n Distributed on behalf of the ASPREE PIs To subscribe to this newsletter please email aspree@monash.edu<\/a><\/p>\nTHE ASPREE PROJECT<\/h2>\n
\u2192\u00a0ASPREE sub-studies<\/a><\/h3>\n
\u2192\u00a0ASPREE publications<\/a><\/h3>\n
\u2192\u00a0Data access<\/a><\/h3>\n
\u2192\u00a0PI updates<\/a><\/h3>\n
THE ASPREE CLINICAL TRIAL\u00a0 (March 2010 – June 2017)<\/h3>\n
THE ASPREE-XT FOLLOW-UP STUDY\u00a0 (June 2017 – current)<\/h3>\n
AT A GLANCE<\/h2>\n
\u00a0Project Features<\/strong><\/h3>\n
\n
Key Publications in NEJM (2018)\u00a0<\/strong><\/h3>\n
\n
ASPREE Sub-studies<\/strong><\/h3>\n
Documentation and data access<\/h3>\n
ASPREE Clinical Trial Protocol<\/h2>\n
Objectives and measures of the ASPREE clinical trial<\/h2>\n
\n
Protocol summary<\/h2>\n
\n
ASPREE-XT Study Protocol<\/h2>\n
Objectives and measures of the ASPREE follow up study, ASPREE-XT<\/h2>\n
\n
Protocol summary<\/h2>\n
\n
Data Access and Collaboration<\/span><\/h2>\n
PI updates for researchers<\/span><\/h2>\n
ASPREE Update #10 (25.08.2026)<\/h3>\n
In the ASPREE RCT phase, there was an increase in cancer mortality noted in the aspirin arm. In the post-intervention phase (ASPREE-XT) there was no difference in cancer mortality risk between those originally assigned to aspirin vs placebo.\u00a0<\/em>
Orchard et al, JAMA Oncology. 2026;12(3):285-294\u00a0 \u00a0 https:\/\/doi.org\/10.1001\/jamaoncol.2025.6196<\/a><\/p>\n
Incident CVD increases frailty burden in older adults, with older age, living alone and living outside a major city associated with greater frailty burden after a CVD event.<\/em>
Phyo AZZ et al, Eur J Prevent Cardiol. 2025\u00a0 https:\/\/doi.org\/10.1093\/eurjpc\/zwaf095<\/a><\/p>\n
Heart stress based on longitudinal changes in NT-proBNP concentration may improve risk stratification of CVD and mortality in older adults.<\/em>
Cai A, et al. Ann Intern Med. 2026\u00a0 \u00a0 https:\/\/doi.org\/10.7326\/ANNALS-26-00245<\/a><\/p>\n
Rory Wolfe (rory.wolfe@monash.edu<\/a>)
Anne Murray (AMurray@bermancenter.org<\/a>)
Andy Chan (ACHAN@mgh.harvard.edu<\/a>)
Joanne Ryan (joanne.ryan@monash.edu<\/a>)<\/p>\n